Wednesday, October 18, 2006 2:25:27 PM
VEGF121/rGel:
9-17-02 PR: The new patent extends the company's broad patent coverage of VTA compositions and treatment methods by providing a unique "targeting agent-therapeutic agent" combination. The targeting agent is the ligand VEGF (vascular endothelial cell growth factor) and the therapeutic agent is a cytotoxic factor termed gelonin. The VEGF121/rGelonin (VEGF/rGel) constructs covered by the new patent complement Peregrine's other VTAs, which use a range of antibody- and ligand-based targeting agents to deliver therapeutic agents such as other cytotoxins, coagulant proteins and radionuclides, into the heart of solid tumors. This patent is particularly designed to protect the ligand-based therapeutic conjugates licensed to SuperGen.
6-11-2002 PR: …new fusion protein that links vascular endothelial growth factor (VEGF) with a toxin (gelonin) targeted and destroyed the blood vessels supplying a tumor. This VEGF construct is a Vascular Targeting Agent (VTA) compound, which Peregrine licensed to SuperGen, Inc. (SUPG) in Feb 2001. The study, which appears in today's issue of the Proceedings of the National Academy of Sciences, involved administering VEGF121/rGelonin (VEGF/rGel) in mice injected with human melanoma and human prostate cancer cells. Researchers found that tumors in mice treated with VEGF/rGel had been reduced by up to 84% compared to tumors in untreated mice. Furthermore, VEGF/rGel selectively destroyed blood vessels supplying human solid tumors without harming the vasculature of normal tissue
2-13-2001 PR: [Deal completed]: "SuperGen will be examining an area of vascular targeting which has great promise as a potential treatment for solid tumors. VEGF has been shown to play an important role in the growth of tumor blood vessels. There is a great deal of work going on in exploring the role that VEGF interactions play in cancer and in other indications. We are confident SuperGen will successfully explore all of these exciting developments."
1-13-2000 PR: signed a letter of intent to license a segment of its Vascular Targeting Agent (VTA) technology, specifically related to Vascular Endothelial Growth Factor (VEGF), with SuperGen, Inc. (NASDAQ:SUPG). The total agreement is approximately $8 million including an upfront payment, milestone payments and a royalty. The VTA technology is Peregrine's proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents. Although VEGF alone is being examined by many companies as a target for anti-angiogenisis agents, Peregrine holds the patents for attaching most therapeutic agents to VEGF for the purpose of targeting them to the tumor vasculature. Dr. Philip Thorpe, (Prof. of Pharmacology at UT-SW Medical Center at Dallas), and the inventor of the VTA technology has shown proof of principle with this technology in several animal models which have been published in peer reviewed scientific journals, including Science in 1997.
Recent CDMO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:22:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:21:22 AM
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM